Regenicin to Form Scientific Advisory Board
NEW YORK Oct. 19 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a development stage biotechnology company, announced today that they have begun identifying candidates for the formation of a Scientific Advisory Board. The board will include thought leaders, scientists and physicians in the fields of regenerative medicine, cellular biology, dermatology and burn and wound treatment. Appointees will play a key role in advising Regenicin on the company's current and future research and development programs as well as in corporate strategies for global expansion.
"We look forward to assembling a team that can provide objective feedback and guidance on Regenicin's efforts to develop and deliver breakthrough treatments for chronic burns and wounds," says Randall McCoy, CEO of Regenicin. "Currently we have identified our key candidates and will announce them individually upon full approval by our board of directors." Regenicin expects to have the full Scientific Advisory Board is in place within the next ninety days.
return to 2010 Press and News Releases
return to Home Page
About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Regenicin(TM), Inc.